Celltech reports Phase II data

Celltech (LSE:CCH; CLL) said preliminary data from a dose-ranging, 203-patient Phase II trial showed 72% of rheumatoid arthritis (RA) patients given a 400 mg once-monthly dose of CDP 870 achieved an A...